EverHint Lens - ImmunityBio, Inc. (IBRX) - (Top Gainer at Yahoo Finance ) - Stock Analysis - February 18, 2026
Analysis Date: 2026-02-18
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
ImmunityBio, Inc. is currently trading at $7.65 (🟢 +27.05% today) with a market capitalization of $7.53B.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV.
Price & Valuation
Current Price: $7.65 (at 11:38 AM ET)
Current Volume: 33.4M (avg 27.6M)
Day Range: $6.06 - $7.76
52-Week Range: $1.83 - $8.28
P/E Ratio: N/A
DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-02-18.
Market Context
Healthcare Sector: 0.65188%
Major Indices:
- S&P 500: $6902.18 (🟢 +0.86%)
- NASDAQ Composite: $22878.81 (🟢 +1.33%)
- Dow Jones Industrial Average: $49802.04 (🟢 +0.54%)
Peer Comparison
Peer comparison (11 companies):
- IBRX - ImmunityBio, Inc. ($7.65, +27.1%) ← Current
- COGT - Cogent Biosciences, Inc. ($37.79, +0.5%)
- DNLI - Denali Therapeutics Inc. ($19.31, +0.2%)
- LQDA - Liquidia Corporation ($34.56, +2.1%)
- BEAM - Beam Therapeutics Inc. ($27.68, +0.7%)
- VRDN - Viridian Therapeutics, Inc. ($28.27, -0.1%)
- GLPG - Galapagos N.V. ($34.41, +1.4%)
- ETNB - 89bio, Inc. ($14.84, 0.0%)
- RCUS - Arcus Biosciences, Inc. ($19.45, +1.1%)
- AGIO - Agios Pharmaceuticals, Inc. ($27.33, -1.7%)
- RXRX - Recursion Pharmaceuticals, Inc. ($3.39, -2.2%)
Financial Performance
Latest Quarter (2025-09-30):
- Revenue: $32.06M
- Net Income: $-67.25M
- EPS: $-0.07
- Revenue Growth (QoQ): +21.3%
Earnings Calendar
Next Earnings Report: 2026-05-11 (Before Market Open)
2 upcoming earnings dates tracked
Most Recent Report: 2025-11-04
- EPS: $-0.07 (Est: $-0.10) ✓ Beat
- Revenue: $0.03B
Historical Data: 45 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $7.00 (-8.5% upside)
- Range: $7.00 - $7.00
- Median: $7.00
Next Quarter Estimates (2028-12-30):
- Revenue: $352.10M
- EPS: $0.14
Analyst Consensus
Overall Rating: Buy
Rating Distribution (54 total ratings):
- 🟢 Buy/Outperform: 49 (90.7%)
- ⚪ Hold/Neutral: 5 (9.3%)
- 🔴 Sell/Underperform: 0 (0.0%)
Recent Analyst Actions:
- HC Wainwright & Co. (2026-01-26): Maintained Buy
- BTIG (2026-01-23): Maintained Buy
- D. Boral Capital (2026-01-23): Maintained Buy
- Piper Sandler (2026-01-20): Maintained Overweight
- D. Boral Capital (2026-01-20): Maintained Buy
Consensus based on 54 analyst ratings from major financial institutions
Trading Signals
Our technical analysis identified 2 trading signal(s) in the last 60 days:
- 2026-01-22: Momentum Swing - breakout @ $7.34
- 2026-01-09: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $2.33
Insider Activity
Recent Transactions (Last 10):
- Buys: 4
- Sells: 6
Notable Transactions:
- 2026-02-10: SOON-SHIONG PATRICK - Buy (Option Exercise, 274,122 shares)
- 2026-02-10: SOON-SHIONG PATRICK - Sell (Tax Withholding, 118,560 shares @ $6.93)
- 2026-02-10: SOON-SHIONG PATRICK - Sell (Option Exercise, 274,122 shares)
Congressional Trading Activity
Tracking recent stock transactions by U.S. Congress members
House of Representatives: 1 transactions tracked
Recent Activity:
- 🔴 Daniel Goldman (NY10): Sale on 2023-03-06 @ $1.76, Amount: $1,001 - $15,000
Congressional trading data sourced from official disclosure filings
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
Recent headlines for ImmunityBio (IBRX) emphasize strong clinical progress with Anktiva and CAR-NK therapies, including durable responses in lymphomas and glioblastoma, alongside explosive revenue growth of 700% and multiple stock surges. Positive FDA engagements outline resubmission paths for expanded approvals, fueling investor optimism. However, recurring investor alerts from Pomerantz Law Firm signal potential legal risks, tempered by overall upward momentum.
Key Themes:
- Clinical trial successes and chemo-free innovations
- Revenue boom and stock surges
- Legal investigations and regulatory progress
Sentiment: Positive (82% confidence)
Recent News
5 most recent articles covering IBRX:
- ImmunityBio: The Story Surrounding Anktiva So Far (seekingalpha.com, 2026-02-18) — Read more
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX (globenewswire.com, 2026-02-17) — Read more
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (prnewswire.com, 2026-02-17) — Read more
- ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia (businesswire.com, 2026-02-17) — Read more
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX (prnewswire.com, 2026-02-12) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-02-18 08:38:19 AM PST
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.